Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
about
Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy.Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide.Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics.BCL-2 as therapeutic target for hematological malignancies.Real world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
P2860
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Venetoclax for chronic lymphoc ...... re, open-label, phase 2 trial.
@en
Venetoclax for chronic lymphoc ...... re, open-label, phase 2 trial.
@nl
type
label
Venetoclax for chronic lymphoc ...... re, open-label, phase 2 trial.
@en
Venetoclax for chronic lymphoc ...... re, open-label, phase 2 trial.
@nl
prefLabel
Venetoclax for chronic lymphoc ...... re, open-label, phase 2 trial.
@en
Venetoclax for chronic lymphoc ...... re, open-label, phase 2 trial.
@nl
P2093
P2860
P921
P1433
P1476
Venetoclax for chronic lymphoc ...... re, open-label, phase 2 trial.
@en
P2093
Ahmed Hamed Salem
Anthony R Mato
Brenda Chyla
Bruce D Cheson
Jalaja Potluri
Jeffrey A Jones
Jennifer Woyach
Maria Verdugo
Matthew S Davids
P2860
P356
10.1016/S1470-2045(17)30909-9
P577
2017-12-12T00:00:00Z